Impact Biomedical (IBO) EBITDA Margin (2022 - 2026)

Impact Biomedical (IBO) posted EBITDA Margin of 32700.0% for Q1 2026, down 520.89% on a QoQ basis from 5266.67% in Q3 2025.

Impact Biomedical (IBO) EBITDA Margin (2022 - 2026) Analysis & Trends

Impact Biomedical's EBITDA Margin history runs 3 years deep, the most recent figure standing at 32700.0% for Q1 2026.

Quarterly EBITDA Margin changed N/A year-over-year to 32700.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 16875.0% (changed N/A YoY) and the FY2022 annual result came in at 6808.0%, changed N/A from the prior year.
EBITDA Margin was 32700.0% for Q1 2026 at Impact Biomedical, down from 5266.67% in the prior quarter.
Across five years, EBITDA Margin topped out at 1500.0% in Q2 2022 and bottomed at 32700.0% in Q1 2026.
A 3-year average of 13984.52% and a median of 10869.05% in 2025 frame the typical range for EBITDA Margin.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	16.51%
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	38.10%
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	17.83%
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	31.68%
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Impact Biomedical	47.44 Mn	50.67 Mn	-	-32,700.00%

Download Data